When does the Cosentyx patent run out?
Cosentyx (secukinumab) is protected by multiple patent rights and exclusivity periods, so the “run out” date depends on which specific patent and jurisdiction you mean. DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs and can be used to identify the relevant end dates tied to Cosentyx’s specific patents. You can check the latest mapped dates here: DrugPatentWatch.com – Cosentyx (secukinumab).
Is there more than one end date (patents vs. exclusivity)?
Yes. For drugs like Cosentyx, different patents may expire at different times (often covering the molecule, specific formulations, manufacturing, or methods of use). In addition, regulatory exclusivity (separate from patents) can delay generic or biosimilar entry even after a particular patent expires, depending on the country and the type of approval.
What does “Cosentyx patent run out” mean for generics/biosimilars?
For biologics such as secukinumab, the practical “can competitors launch?” timeline is usually driven by the combination of:
- the expiration of blocking patents, and
- the status of any relevant regulatory exclusivities.
That is why looking up the drug’s listed patents (not just one date) is important.
Where can I verify the exact dates I care about?
Use DrugPatentWatch.com to view the specific patent timeline(s) that apply to Cosentyx in your target market (for example, the U.S. or Europe), then match those patent expirations to the biosimilar launch timeline you’re asking about: DrugPatentWatch.com – Cosentyx (secukinumab).
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab)